Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Scroll down and select country
MEBO TMAU TESTING CURRENTLY SUSPENDED INDEFINITELY

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Monday, September 9, 2019

uBiome restructuring not affecting MEBO study

On September 4th, MEBO received an email from the Research and Collaborations Lead scientist, who has been providing us with ongoing support on the MEBO Clinical Trial, NCT03582826, Microbial Basis of Systemic Malodor and PATM Conditions, a research study funded by a uBiome research grant. In her email, she informs us that on the previous day, uBiome filed for Chapter 11 Bankruptcy protection. She further explains:
uBiome filed for Chapter 11 Bankruptcy protection. This a necessary step in our ongoing restructuring and will allow our business to move forward as a whole. I wanted to ensure you that business is currently continuing as normal, and our laboratory operations will continue.

We are dedicated to continuing our research partnerships as they are an essential element of the future of the company, and I want to emphasize that our support of your ongoing studies will not be affected.

In addition, I asked the uBiome scientist why the new TMA results category was removed from each participant's personal online report, to which she replied:
I am so sorry that it has been removed, I know it was useful for you and the community.

In the last few weeks/months we have been updating Explorer to make sure what we are saying is scientifically valid and can stand up to scrutiny. I am not on the product team so I was not involved in the decision, but the decision to remove that was most likely based on what they felt was substantial scientific evidence to be able to report those results.

She added that she will mention it again to the product team when they make more updates.

At the present time, uBiome continues to offer the same Gut Explorer test used for the above mentioned MEBO clinical trial.

MEBO Dynamics of the Gut Microbiota 
in Idiopathic Malodor Production


This MEBO clinical trial is in its final stages of data analysis and will soon publish the conclusion. Meanwhile, the updates on findings by Irene Gabashvili, PhD., Principal Investigator, can be found in the following posts in the Aurametrix Blog:
  1. Alloprevotella: September 4, 2019
  2. Epulopiscium: August 19, 2019
  3. Friends and Stars: August 14, 2019
  4. PATM and TMAU: August 5, 2019
  5. Feeding microbiomes: July 21, 2019
  6. Blood type: June 2, 2019
  7. First 41 results: November 21, 2018
  8. Press Release: November 28, 2018
  9. What we hope to learn: June 27, 2018
  10. MEBO Microbiome Study: June 215, 2018
  11. Microbes of anti-social odor: March 14, 2018
  12. Crowdsourcing precision medicine: February 23, 2018
We are most grateful to uBiome for their very generous research grant and to Irene for her dedication and leadership in this research study.
María

María de la Torre
Founder and Executive Director

A Public Charity
maria.delatorre@meboresearch.com
www.meboresearch.org
www.mebo.com.br/
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)



SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.


get New Posts by EMAIL : Enter your email address :



A EURORDIS and NORD Member Organization

0 comments:

Post a Comment